Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington. Show more
Location: 18702 North Creek Parkway, Bothell, WA, 98011, United States | Website: https://immunome.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
791.2M
52 Wk Range
$5.15 - $16.55
Previous Close
$9.09
Open
$9.08
Volume
1,162,404
Day Range
$8.92 - $9.46
Enterprise Value
527.3M
Cash
268M
Avg Qtr Burn
-44.67M
Insider Ownership
11.50%
Institutional Own.
87.04%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IMM-BCP-01 Details COVID-19 | Phase 1b Data readout |